Shares of Mankind Pharma surged around 11% over two trading sessions after the pharmaceutical company reported strong second-quarter earnings, supported by domestic demand, improved operating margins and robust export growth. Brokerages see further growth potential, although the sustainability of domestic performance remains a key monitorable.

Mankind Pharma Share Price Jumps After Q2 Earnings

Shares of Mankind Pharma extended their rally on Tuesday, October 27, 2026, as investors responded positively to the company’s strong financial performance for the September quarter of FY27.

The stock rose as much as 6.5% to ₹2,451.95 on the BSE during intraday trade, extending gains from the previous session. The pharmaceutical company’s shares had advanced approximately 11% over two trading days following the announcement of its quarterly results.

The stock was trading significantly higher even as the benchmark Sensex remained under pressure, indicating that the earnings announcement had become a key driver of investor sentiment.

Mankind Pharma had previously touched a 52-week high of ₹2,640.30 on July 29, 2026. Despite the latest recovery, investors will assess whether the earnings momentum can support further gains and help the stock move towards its previous peak.

Net Profit Rises 37.7% to ₹716 Crore

Mankind Pharma reported a 37.7% year-on-year increase in consolidated profit after tax (PAT) to ₹716 crore in Q2FY27, compared with ₹520 crore in the corresponding quarter of the previous financial year.

The improvement in profitability was supported by strong domestic demand, higher revenue and better operating margins.

Revenue from operations increased 17.3% year-on-year to ₹4,338 crore from ₹3,697 crore in Q2FY26. The growth indicates that the company continued to expand its business despite the competitive environment in India's pharmaceutical market.

The company’s domestic business remained the principal revenue contributor, accounting for approximately 86% of overall revenue. Revenue from India operations increased 14.8% to ₹3,657 crore during the September quarter.

The strong contribution from the domestic market is important for Mankind Pharma because its performance depends significantly on prescription medicines, consumer healthcare products and the strength of its distribution network across India.

EBITDA Grows 27.2% as Operating Margins Improve

Mankind Pharma also reported a healthy improvement in operating profitability during Q2FY27.

EBITDA increased 27.2% year-on-year to ₹1,175 crore. The EBITDA margin expanded by 210 basis points to 27.1%, compared with 25% in the year-ago quarter.

The improvement in margins indicates that operating earnings grew faster than revenue, suggesting benefits from stronger sales and operating leverage.

Higher revenue can improve profitability when companies are able to distribute fixed costs across a larger sales base. However, the sustainability of margin expansion depends on product mix, input costs, marketing expenditure, research and development investments, and the competitive intensity of the pharmaceutical market.

Mankind Pharma’s management retained its FY27 EBITDA margin guidance of 25.5–26.5%, while indicating that research and development expenditure is expected to remain at 2.8–3% of revenue.

The guidance will be an important benchmark for investors as they evaluate the company’s ability to sustain profitability through the remainder of the financial year.

Export Business Delivers Strong Growth

Mankind Pharma’s international business emerged as another important growth driver during the quarter.

According to brokerage commentary, exports increased 33% year-on-year, significantly exceeding the 15% growth estimate cited by Jefferies.

The growth was broad-based across the company’s core Mankind business and its BSV portfolio. BSV recorded growth of 34%, Mankind US increased 29%, and other international markets expanded 37%, according to the brokerage’s analysis.

The company’s management has guided for approximately 20% constant-currency export growth in FY27, supported by anticipated strength across its core international business and BSV portfolio.

Strong exports can help pharmaceutical companies diversify revenue beyond the domestic market and reduce dependence on a single geography. However, international expansion also involves regulatory requirements, product approvals, pricing pressures, currency movements and competition from established global pharmaceutical companies.

Investors will therefore monitor whether the export business can sustain its growth trajectory in subsequent quarters and contribute meaningfully to overall earnings.

Chronic Medicines and Domestic Volumes Remain Key Growth Drivers

Mankind Pharma’s domestic performance has been supported by demand for chronic medicines, which are used to manage long-term conditions such as diabetes, cardiovascular diseases and other persistent health disorders.

The increasing contribution of chronic therapies can be strategically beneficial for pharmaceutical companies because these treatments often involve long-duration medication and recurring prescriptions.

However, the pace of growth across chronic and acute therapies can vary depending on seasonal demand, prescription trends, product launches and competitive activity.

JM Financial Institutional Securities noted that the improving domestic volume trajectory was encouraging and could signal a gradual return towards historical outperformance against the Indian Pharmaceutical Market (IPM).

The brokerage also cautioned that Q2 is seasonally favourable for companies with significant acute-therapy exposure. Consequently, the sustainability of domestic growth over the coming quarters remains an important factor to watch.

Management is targeting growth of approximately 1.1–1.2 times the growth of the Indian Pharmaceutical Market over the next two quarters. Achieving this objective would require continued volume growth, competitive product offerings and effective distribution.

Consumer Healthcare Business Under Watch

While the core pharmaceutical business and exports delivered encouraging growth, the consumer healthcare segment remains an area requiring close monitoring.

According to Systematix Institutional Research, Mankind Pharma expects high-single-digit growth in consumer healthcare during FY27, with a recovery anticipated in FY28.

Consumer healthcare businesses can provide pharmaceutical companies with opportunities to expand brand recognition and reach customers beyond prescription medicines. However, they also face competition from established consumer brands, regional players and new product launches.

The segment’s recovery will depend on demand conditions, distribution strength, marketing effectiveness and the company’s ability to improve product-level growth.

Investors will look for evidence that the anticipated recovery translates into stronger revenue and profitability over the medium term.

What Brokerages Are Saying About Mankind Pharma

JM Financial Upgrades Rating to ‘Add’

JM Financial Institutional Securities upgraded Mankind Pharma to ‘Add’ following the recent correction in the stock, citing a relatively more favourable risk-reward profile for its domestic business recovery thesis.

The brokerage said sustained volume-led outperformance would be necessary to support further upgrades. It valued the company at 22 times September 2028 estimated EBITDA, arriving at a target price of ₹2,638.

The assessment highlights the importance of continued domestic volume growth rather than relying solely on one strong quarterly performance.

Jefferies Maintains ‘Buy’ Rating

Jefferies maintained its ‘Buy’ rating on Mankind Pharma, citing an improving growth outlook and easing challenges related to the restructuring of the core business and integration of BSV.

The brokerage raised its EBITDA estimates by 3%, reflecting the potential benefits of stronger revenue growth and operating leverage.

Jefferies valued the company at 22 times December 2028 estimated EBITDA and set a target price of ₹2,900.

The brokerage’s outlook is supported by strong export growth and expectations of continued momentum across the company’s domestic and international operations.

Systematix Sees Support From Chronic Growth and Exports

Systematix Institutional Research expects improving domestic volumes, a rising contribution from chronic therapies and sustained export momentum to support growth.

The brokerage also highlighted the company’s domestic market outperformance target and the expected recovery in consumer healthcare as factors to monitor.

Although the overall brokerage commentary is constructive, the forecasts remain dependent on execution and the sustainability of the growth rates reported in Q2FY27.

Key Risks Investors Should Monitor

Despite the strong quarterly results, several factors could influence Mankind Pharma’s future performance.

1. Sustainability of domestic growth: The company needs to demonstrate that the latest improvement in domestic sales and volumes can continue beyond a seasonally favourable quarter.

2. Margin performance: Maintaining EBITDA margins within the guided range will depend on product mix, operating costs, competition and investment requirements.

3. Export growth: The company’s international business has delivered strong growth, but investors will need to assess whether this momentum continues throughout FY27.

4. Consumer healthcare recovery: The expected improvement in FY28 remains a forward-looking outlook and will depend on execution and market conditions.

5. Valuation and market volatility: A sharp rise in the share price following quarterly results can increase expectations for future earnings. If subsequent performance falls short of those expectations, the stock could face renewed volatility.

6. Regulatory and competitive pressures: Pharmaceutical companies operate in a highly regulated environment and face risks relating to product approvals, quality standards, pricing and competition.

These factors will determine whether Mankind Pharma can convert its strong quarterly performance into sustained earnings growth.

Market Outlook

Mankind Pharma’s Q2FY27 results have strengthened the near-term earnings narrative, with net profit rising 37.7% to ₹716 crore, revenue increasing 17.3% to ₹4,338 crore and EBITDA margins expanding to 27.1%.

The strong domestic business, improving operating leverage and 33% export growth have encouraged brokerages to maintain a constructive view of the company’s prospects. However, the sustainability of domestic volume growth, execution of the FY27 margin guidance and the recovery of consumer healthcare remain important monitorables.

The stock’s approximately 11% rally over two sessions reflects improving investor confidence following the results. Nevertheless, the latest gains should be evaluated alongside the company’s earnings outlook, valuation and the target prices issued by individual brokerages.

For investors, the next few quarters will be important in establishing whether the company can maintain its growth momentum and deliver on management’s expectations. Strong results provide a positive starting point, but continued execution will be necessary to justify the market’s expectations.